Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT05600127
- Locations
- 🇳🇱
Amphia ziekenhuis, Breda, Brabant, Netherlands
🇳🇱Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands
🇳🇱Erasmus MC, Rotterdam, Zuid Holland, Netherlands
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT05568407
- Locations
- 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷Hospital Mãe de Deus/Aesc, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷Hospital Alemão Oswaldo Cruz, Sao Paulo, SP, Brazil
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 79
- Registration Number
- NCT05431777
- Locations
- 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵Asahi General Hospital, Asahi, Chiba, Japan
🇯🇵Ogaki Municipal Hospital, Ogaki, Gifu, Japan
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Genome & Company
- Target Recruit Count
- 42
- Registration Number
- NCT05419362
- Locations
- 🇰🇷
Ajou University Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
- Conditions
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 72
- Registration Number
- NCT05396833
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Augusta University - formerly Georgia Regents University, Augusta, Georgia, United States
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 130
- Registration Number
- NCT05394493
- Locations
- 🇬🇧
Pfizer Ltd, Sandwich, Kent, United Kingdom
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 106
- Registration Number
- NCT05366725
- Locations
- 🇬🇧
University Hospitals Bristol, Bristol, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 256
- Registration Number
- NCT05327530
- Locations
- 🇺🇸
Beacon Cancer Care, Coeur d'Alene, Idaho, United States
🇺🇸University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN), Kansas City, Kansas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 173
- Registration Number
- NCT05291156
- Locations
- 🇮🇹
A.O.U. Ospedali Riuniti, Ancona, Italy
🇮🇹A.O. San Giuseppe Moscati, Avellino, Italy
🇮🇹Centro di Riferimento Oncologico (C.R.O.), Aviano, Italy
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Aulos Bioscience, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT05267626
- Locations
- 🇺🇸
University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.